TP53 and ductal breast carcinoma in situ: We then compared the expression of promising DCIS risk biomarkers (Ki-67, p53 and p16) among the different DCIS subgroups, classified based on adjacent TDLU and IDC, to examine whether an “aggressive” DCIS subpopulation existed.